Kei Kishimoto

Kei Kishimoto

Company: Selecta Biosciences

Job title: Chief Scientific Officer


Kei Kishimoto is the Chief Scientific Officer of Selecta Bioscience, a clinical stage company completing Phase 3 trials of its ImmTOR tolerogenic nanoparticle technology. Kei received his PhD in immunology at Harvard University and completed his post-doctoral training at Stanford University.


Industry Leaders’ Panel: Evaluating Progress of AAV Redosing Developments in 2023 3:30 pm

Outlining the current state of play between ‘one and done’ and ‘low and slow’ approaches? How is the investment landscape of gene therapies impacting developments in redosing? Where are we making significant progress in the field?Read more

day: Pre-Conference Day

Can you Re-Dose AAV at High Vector Doses? 2:15 pm

The ability to administer multiple doses of AAV vector could provide a potential strategy to mitigate toxicities typically associated with vector doses of 1E14 vg/kg or higher However, such a strategy would require the ability to re-dose at vector doses of ~5E13 vg/kg, which presents a considerable immunological challenge Presenting data to investigate combination treatment…Read more

day: Pre-Conference Day

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.